RESUMEN
BACKGROUND: Lower respiratory tract infections (LRTIs) have an immediate significant impact on morbidity and mortality among older adults. However, the impact following the infectious period of LRTI remains understudied. We aimed to assess the short- to long-term impact of LRTIs on hospitalization, mortality, and healthcare utilization in older adults. METHODS: Data from the Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was analyzed, with data from 2001 to 2019 for mortality and 2001-2016 for healthcare utilization. LRTI-exposed participants were identified and matched with LRTI-nonexposed based on sociodemographics, lifestyle factors, and functional and clinical characteristics. Statistical models evaluated post-LRTI hospitalization risk, days of inpatient hospital admissions, healthcare visits, and mortality. RESULTS: 567 LRTIs-exposed participants during the study period and were matched with 1.701 unexposed individuals. LRTI-exposed individuals exhibited increased risk of hospitalization at 1-year (HR 2.14, CI 1.74, 2.63), 3-years (HR 1.74, CI 1.46, 2.07), and 5-years (HR 1.59, CI 1.33, 1.89). They also experienced longer post-LRTI hospital stays (IRR 1.40, CI 1.18, 1.66), more healthcare visits (IRR 1.47, CI 1.26, 1.71), specialist-care visits (IRR 1.46, CI 1.24, 1.73), and hospital admissions (IRR 1.57, CI 1.34, 1.83) compared to nonexposed participants over 16-years of potential follow-up. Additionally, the 19-year risk of mortality was higher among LRTI-exposed participants (HR 1.45, CI 1.24, 1.70). Men exhibited stronger associations with these risks compared to women. CONCLUSIONS: LRTIs pose both short- and long-term risks for older adults, including increased risks of mortality, hospitalization, and healthcare visits that transpire beyond the acute infection period, although these effects diminish over time. Men exhibit higher risks across these outcomes compared to women. Given the potential preventability of LRTIs, further public health measures to mitigate infection risk are warranted.
Asunto(s)
Hospitalización , Aceptación de la Atención de Salud , Infecciones del Sistema Respiratorio , Humanos , Masculino , Suecia/epidemiología , Femenino , Anciano , Infecciones del Sistema Respiratorio/mortalidad , Infecciones del Sistema Respiratorio/epidemiología , Hospitalización/estadística & datos numéricos , Anciano de 80 o más Años , Aceptación de la Atención de Salud/estadística & datos numéricos , Estudios de CohortesRESUMEN
Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP's target populations more effectively.
Asunto(s)
Literatura Gris , Infecciones Neumocócicas , Adulto , Humanos , Vacunación , Vacunas Neumococicas , Infecciones Neumocócicas/prevención & control , Infecciones Neumocócicas/epidemiología , Vacunas Conjugadas , Europa (Continente)/epidemiología , Programas de InmunizaciónRESUMEN
AIM: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM. MATERIALS & METHODS: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers. RESULTS & CONCLUSION: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.
RESUMEN
BACKGROUND: Despite its high incidence among children under the age of five, little is known about the burden of pediatric gastroenteritis outside the medical setting. The objective of this study was to describe the burden of acute gastroenteritis among children residing in the United Arab Emirates, including those not receiving medical care. METHODS: A quantitative cross-sectional survey of 500 parents of children under 5 years of age who had suffered from acute gastroenteritis the preceding three months was conducted in the cities of Abu Dhabi and Al Ain. Data collected included respondent characteristics, disease symptoms, medical care sought, and parental expenditures and work loss. Data were analyzed using parametric and non-parametric statistical methods. RESULTS: Vomiting and diarrhea episodes lasted on average between 3 and 4 days. Overall, 87% of parents sought medical care for their children; 10% of these cases required hospitalization with an average length of stay of 2.6 days. When medical care was sought, the average parental cost per gastroenteritis episode was US$64, 4.5 times higher than with home care only (US$14). Nearly 60% of this difference was attributable to co-payments and medication use: 69% of children used oral rehydration solution, 68% antiemetics, 65% antibiotics and 64% antidiarrheals. Overall, 38 parents missed work per 100 gastroenteritis episodes for an average of 1.4 days. CONCLUSIONS: Given its high incidence, pediatric gastroenteritis has an important financial and productivity impact on parents in the United Arab Emirates. To reduce this impact, efforts should be made both to prevent acute gastroenteritis and to optimize its treatment.
Asunto(s)
Costo de Enfermedad , Gastroenteritis/economía , Enfermedad Aguda , Preescolar , Estudios Transversales , Diarrea/economía , Diarrea/etiología , Diarrea/terapia , Gastroenteritis/complicaciones , Gastroenteritis/diagnóstico , Gastroenteritis/terapia , Gastos en Salud/estadística & datos numéricos , Encuestas Epidemiológicas , Hospitalización/economía , Hospitalización/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Permiso Parental/estadística & datos numéricos , Emiratos Árabes Unidos , Vómitos/economía , Vómitos/etiología , Vómitos/terapiaRESUMEN
OBJECTIVE: Assess long-term cost-effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models based on clinical trial efficacy data. METHODS: Incremental costs and Quality Adjusted Life Years (QALYs) associated with rivastigmine patch and capsule treatment versus best supportive care (BSC) were calculated using two economic models, one based solely on Mini-Mental State Examination (MMSE) scores, and one also incorporating activities of daily living (ADL) scores. The clinical pathway was populated with data from a clinical trial of rivastigmine patch (9.5 mg/24 h) and capsules (12 mg/day) versus placebo. Costs were based on the UK health and social care costs and basic UK National Health Service (NHS) prices. Disease progression was modelled beyond the trial period over 5 years using published equations to predict natural decline in AD patients. Base case costing variables included drugs, clinical monitoring, and institutionalization. RESULTS: The MMSE model estimated incremental costs per QALY of £10 579 for rivastigmine patch and £15 154 for capsule versus BSC. The MMSE-ADL model estimated incremental costs per QALY of £9114 for rivastigmine patch and £13 758 for capsules. The main difference between the models was a greater number of institutionalized days avoided for rivastigmine versus BSC estimated by the MMSE-ADL model. CONCLUSIONS: Both the MMSE and MMSE-ADL models suggest that rivastigmine patch and capsules are cost-effective treatments versus BSC. Incorporating ADL evidence makes a marginal but important difference to estimates in this case. Future economic evaluations of AD treatment should include measures of both cognition and functioning.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Fármacos Neuroprotectores/economía , Fenilcarbamatos/economía , Parche Transdérmico/economía , Escalas de Valoración Psiquiátrica Breve , Análisis Costo-Beneficio , Progresión de la Enfermedad , Femenino , Humanos , Institucionalización/economía , Masculino , Modelos Económicos , Fármacos Neuroprotectores/administración & dosificación , Fenilcarbamatos/administración & dosificación , Años de Vida Ajustados por Calidad de Vida , Análisis de Regresión , Rivastigmina , Apoyo Social , Reino UnidoRESUMEN
OBJECTIVE: A transmission dynamic model was used to assess the epidemiological and economic impact of a quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine in preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN 2/3), CIN 1 and genital warts in Hungary. METHODS: The routine vaccination of 12-year-old girls and the routine vaccination of 12-year-old girls plus a temporary catch-up programme for girls and women aged 12-24 years was evaluated. RESULTS: The model projected that at year 100, both strategies could reduce the incidence of HPV 6/11/16/18-related cervical cancer, CIN 2/3, CIN 1 and genital warts cases among Hungarian women by 90%, 90%, 85% and 93%, respectively. Twenty-five years after the introduction of HPV vaccination in the population, routine vaccination of girls by the age of 12 reduced the cumulative number of cases of cervical cancer, CIN 2/3, CIN 1 and genital warts by 685, 13,473, 3,423 and 163,987, respectively. The incremental cost-effectiveness ratios of the two vaccination strategies were 9,577 and 10,646 per quality-adjusted life-year (QALY) gained over a time horizon of 100 years. KEY LIMITATIONS: The model did not account for the health and economic impact of other HPV diseases which may result from HPV 16, 18, 6, and 11 infections such as vaginal, vulvar, penile, anal and head-neck cancers, and recurrent respiratory papillomatosis. Epidemiological data from Hungary on these other HPV diseases as well genital warts are needed. CONCLUSION: A quadrivalent HPV vaccination programme can reduce the incidence of cervical cancer, CIN and genital warts in Hungary at a cost-per-QALY ratio within the range defined as cost effective.
Asunto(s)
Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/economía , Displasia del Cuello del Útero/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Adolescente , Niño , Análisis Costo-Beneficio/estadística & datos numéricos , Femenino , Humanos , Hungría/epidemiología , Programas de Inmunización/economía , Programas de Inmunización/estadística & datos numéricos , Incidencia , Modelos Económicos , Modelos Teóricos , Infecciones por Papillomavirus/economía , Infecciones por Papillomavirus/epidemiología , Años de Vida Ajustados por Calidad de Vida , Neoplasias del Cuello Uterino/economía , Neoplasias del Cuello Uterino/epidemiología , Vacunación/economía , Vacunación/estadística & datos numéricos , Adulto Joven , Displasia del Cuello del Útero/economía , Displasia del Cuello del Útero/epidemiologíaRESUMEN
OBJECTIVES: To illustrate how conjoint analysis can be used to identify patient preferences for healthcare policies, and to measure preferences for healthcare reforms in Hungary. DATA SOURCE/STUDY SETTING: Data was collected via a mail-based survey and a direct survey administered in a rheumatology out-patient centre in Flór Ferenc County Hospital, Budapest, Hungary (n = 86). STUDY DESIGN: We designed and administered a conjoint analysis to the study population. Attributes and attribute levels were developed on the basis of key informant interviews and a literature review. Additional demographic, occupation and healthcare utilisation data were also collected using surveys. A mixed effects linear probability model was estimated holding respondent characteristics constant and correcting for clustering. DATA COLLECTION: Conjoint analysis questionnaires were administered by a physician to 50 consecutive rheumatology patients in a clinic and an additional 36 were mailed by post. PRINCIPAL FINDINGS: The response rate for the physician-administered survey was 98% (but 18% of these were excluded for inconsistent preferences) and 53% for the mail survey, leaving a final sample of 59. Regression results (R2 = 56.8%) indicated that patients preferred a health system that was not cost constrained (p = 0.003), was based on solidarity (p < 0.001) and where patients were empowered (p = 0.024). Further, they would choose a system with no choice of provider to avoid co-payments (p = 0.005). CONCLUSIONS: This study demonstrates that patients have clear preferences for healthcare system policy. In order to develop evidence-based healthcare policy and to empower patients in the healthcare system, methods such as conjoint analysis offer a simple yet theoretically grounded basis for policy making.
Asunto(s)
Reforma de la Atención de Salud/métodos , Modelos Econométricos , Satisfacción del Paciente/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Deducibles y Coseguros , Unión Europea , Femenino , Costos de la Atención en Salud , Reforma de la Atención de Salud/economía , Encuestas de Atención de la Salud/métodos , Necesidades y Demandas de Servicios de Salud/economía , Hospitales de Condado , Humanos , Hungría , Masculino , Persona de Mediana Edad , Servicio Ambulatorio en Hospital/estadística & datos numéricos , Participación del Paciente/economía , Satisfacción del Paciente/economía , Calidad de la Atención de Salud/economía , Análisis de Regresión , Reumatología , Encuestas y CuestionariosRESUMEN
In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular; endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill. HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible overtreatment can hardly be analysed accurately.